By Fineline Cube 
China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as Chief Medical Officer (CMO), effective from June 9, 2025. Based in China, Dr. Wu will oversee clinical team development, trial execution, and regulatory strategy, reporting directly to Dr. Wenzhi Tian, Founder, Chairman, CEO, and Chief Scientific Officer of ImmuneOnco.
Leadership and Experience
With over 13 years of specialization in hematology and immuno-oncology drug development, Ms. Wu has held leadership roles at Janssen Pharmaceuticals, Roche, and Shanghai Fosun Pharma, where she served as Senior Vice President of R&D and China CMO for Oncology. She has led over 40 Investigational New Drug (IND) applications and spearheaded 5 New Drug Applications (NDAs), resulting in 3 approvals and 3 Breakthrough Therapy designations.
Key Achievements
Ms. Wu played a pivotal role in accelerating the approval of the MEK inhibitor lumosertib, which is China’s first-in-class treatment for histiocytic disorders/tumors and pediatric neurofibromatosis type 1-related plexiform neurofibromas, addressing significant unmet medical needs.
Industry Involvement
In addition to her industry leadership, Ms. Wu is an active member of the Chinese Society of Clinical Oncology (CSCO) Clinical Trial Committee and the China Pharmaceutical Innovation and Research Development Association (PhIRDA) Oncology Drug Clinical Research Committee.-Fineline Info & Tech